In vivo, blockade of CXCR3 abrogated the suppression of GBM growth observed in the EMP3_KO group but promoted tumorigenesis in the EMP3_Scra group and led to significantly poorer survival. This evidence concerns the gene CXCR3 and glioblastoma.